logo
Plus   Neg
Share
Email

AstraZeneca Announces Approval For Tagrisso In China - Quick Facts

AstraZeneca (AZN.L,AZN) said Tagrisso has received marketing authorisation in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer. The company said the approval from China's National Medical Products Administration followed the Priority Review Pathway and is based on results from the Phase III FLAURA trial.

Tagrisso was approved in China in 2017 and added to the National Reimbursement Drug List effective from January 2019 for the 2nd-line treatment of adult patients with locally-advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>